Neurological Dry Eye Study Stimulating Both Lacrimal and Vagus Nerves
Not Applicable
Not yet recruiting
- Conditions
- Dry EyeDry Eye Disease
- Interventions
- Dietary Supplement: NeuroTearsDietary Supplement: Placebo
- Registration Number
- NCT06271005
- Lead Sponsor
- Genetic Disease Investigators
- Brief Summary
This is a study on neurological dry eye disease, focusing on a patented over-the-counter supplement supporting tear production neurologically, including the lacrimal and vagus nerves.
- Detailed Description
Chronic inflammation is implicated in the majority of chronic dry eyes. The parasympathetic nervous system is responsible for both basal tear secretion (the aqueous layer) by the lacrimal functional unit, and is responsible for controlling many aspects of chronic inflammation via the vagus nerve.
This study will document its effects on dry eyes, in addition to other symptoms/signs of low parasympathetic nervous system functioning using an over-the-counter supplement.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
- Must have dry eye (OSDI score 30 and above)
- Tear break up time of less than or equal to 7 seconds
- Must be able to come for baseline tests and again at 4 weeks
Exclusion Criteria
- Demodex
- Corneal scarring
- must not take Physostigmine (glaucoma), Pyridostigmine (Mestinon), Neostigmine (for Myasthenia Gravis); Aricept (for Alzheimer's), or ingredients to NeuroTears
- No known allergies to ingredients in NeuroTears
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment with NeuroTears NeuroTears - Placebo Placebo -
- Primary Outcome Measures
Name Time Method OSDI 4 weeks Ocular Surface Disease Index
- Secondary Outcome Measures
Name Time Method